This Act gives the Government of Yukon—and separately the Government of Canada—a statutory, direct cause of action to recover the present value of past and expected future health‑care expenditures tied to opioid‑related disease, injury or illness from manufacturers, wholesalers or consultants involved with opioid products. The claim can target particular insured individuals or be brought on an aggregate (population) basis and is not brought by subrogation but in the governments’ own right.
Beyond creating the cause of action, the Act rewrites litigation mechanics: it admits population and epidemiological evidence, creates evidentiary presumptions when certain thresholds are met, supplies market‑share formulas to quantify liability, allows joint and several liability (including for directors and officers) subject to limited defences, extends and revives limitation windows, and grants the Executive power to regulate active ingredients and opioid definitions. Those procedural and substantive changes make Yukon a litigation model for recovering public health costs from the opioid supply chain.
At a Glance
What It Does
The Act authorizes Yukon and Canada to sue manufacturers, wholesalers and consultants for the present value of health‑care benefits (past and future) attributable to opioid‑related harms, either for specific insured individuals or for an aggregated population. It establishes statutory presumptions (for aggregate claims), permits population‑based evidence and sets formulas to allocate liability by market share or risk contribution.
Who It Affects
Direct targets are manufacturers, wholesalers and consultants as defined (including trade associations meeting the definition), plus directors and officers who authorized or participated in corporate misconduct. It also affects Yukon and federal health administrators, class‑action counsel, expert epidemiologists and courts handling anonymized, population‑level discovery.
Why It Matters
The Act lowers procedural barriers to government recovery of public health costs by allowing aggregate proof and presumptions rather than requiring individual causation proofs; it specifies how to apportion liability and creates personal exposure for corporate leaders. For insurers, manufacturers and counsel, the Act alters litigation strategy, evidentiary practice and potential financial exposure while signaling a territorial model other jurisdictions could copy.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Act creates two separate statutory claims: one the Government of Yukon can bring in its own name and one the Government of Canada can bring in its own name. Each claim seeks the present value of health‑care benefits that were provided or that can reasonably be expected to be provided as a result of opioid‑related disease, injury or illness. “Health‑care benefits” is tied to Yukon and federal insured programs and also includes other programs and travel costs identified in Yukon statutes; the Act requires courts to assess costs on a present‑value basis.
For recovery on an aggregate basis the Act sets a three‑part threshold the government must prove on a balance of probabilities: the defendant breached a duty to Yukon‑insured persons, the type of opioid product can cause or contribute to harm, and the defendant’s product was offered for sale in Yukon during the breach period. If those facts are proven, the Act creates two statutory presumptions: that the exposed population would not have used the product but for the breach, and that a portion of that population suffered harm because of the use or exposure.
Those presumptions allow the court to quantify aggregate health‑care costs and assign each defendant liability proportionate to its market share for the product type unless the defendant rebuts causation or contribution.When individual causation is contested or it is impossible to identify which defendant caused a particular exposure, the Act allows liability to be apportioned by each defendant’s contribution to risk. The statute lists concrete factors the court must consider in that apportionment—time on market, market share, potency, promotional spend, leadership role, warnings, testing, and whether promotion continued after knowledge of risk—so judges have a statutory menu for allocating percentages.Evidence rules shift the battlefield.
The Act explicitly admits statistical, epidemiological and sampling‑based evidence to establish causation and quantify costs, and it limits compellability of individual health records and testimony: identifying individual insured persons is unnecessary for aggregate claims, health records are not generally compellable, and discovery of a statistically meaningful sample is the prescribed route for testing claims, with identifiers removed before disclosure. The statute also prescribes a market‑share calculation for manufacturers and wholesalers (simple ratio formulas tied to quantities manufactured/promoted and quantities purchased/dispensed in Yukon).Finally, the Act changes limitation and remedial mechanics: it gives the statute retroactive effect, revives certain earlier‑dismissed suits that were barred by limitation rules, preserves ongoing out‑of‑territory class proceedings but requires them to continue under Yukon law where Yukon is a class member, and restricts the legal effect of prior agreements that purport to bind Yukon — while allowing Yukon to deduct any settlement proceeds already received.
The Five Things You Need to Know
The Act lets Yukon and Canada recover the present value of both past and expected future government health‑care spending tied to opioid harms, not merely past expenditures.
For aggregate claims the court must presume (if the government proves three threshold facts) that exposed insured populations would not have used the product but for the breach and that a portion were harmed; liability then follows the defendant’s market share for that product type.
The statute supplies explicit market‑share formulas: for manufacturers A = (B/C)×100% (B = quantity the manufacturer distributed/promoted in Yukon; C = total quantity purchased/dispensed for health‑care in Yukon) and for wholesalers D = (E/F)×100%.
The Act makes directors and officers jointly and severally liable with a corporation for opioid‑related wrongs unless they prove they did not know and could not have known of the wrongdoing or they exercised reasonable diligence to prevent it.
The Act extends and revives limitation windows: government proceedings begun before the section came into force or within 15 years after are not barred; suits dismissed solely as time‑barred are revived.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Who counts as a manufacturer, wholesaler or consultant and what an opioid product is
The Act’s definitions are detailed and operational. “Manufacturer” reaches current or past manufacturers and anyone who derived at least 10% of consolidated revenues from manufacture or promotion, and it expressly includes trade associations that primarily promoted manufacturers’ interests. The Schedule lists named opioids and the Executive can add active ingredients by regulation, so legal status can change without amending the primary text. Practitioners, types of product forms, and what counts as health‑care benefits are all spelled out — which constrains later arguments about standing and the scope of recoverable programs.
Governments sue in their own right; individual or aggregate claims allowed
Each government brings a distinct, non‑subrogated claim for health‑care costs. The government can sue for specific insured individuals or, crucially, on an aggregate basis for a population of insured persons. The Act clarifies that the government’s recovery does not depend on whether private plaintiffs recovered damages — the government’s right is independent — which affects settlement incentives and coordination with class counsel.
Thresholds, presumptions and market‑share allocation for aggregate claims
If the government proves (balance of probabilities) the defendant breached a duty to Yukon persons, the product can cause harm, and the defendant offered the product in Yukon during the breach period, the court must draw statutory presumptions that facilitate aggregate causation and quantification. Once the presumptions apply the court determines aggregate cost and allocates liability to defendants by market share, subject to reduction if a defendant rebuts causation. This shifts the burden of individualized causation onto defendants when aggregate predicates are met.
Allows statistical, epidemiological and sampling evidence — limited access to individual health records
The Act expressly admits statistical and population‑level evidence to establish causation and quantify losses and restricts compellability of individual health records and testimony. Defendants can, however, apply for discovery of a statistically meaningful sample, and any disclosed documents must be anonymized. That framework aims to balance privacy with defendants’ right to test claims but leaves methodological battles over ‘statistically meaningful’ samples to the courts.
15‑year window, revival of time‑barred actions, and retroactive application
The Act removes limitation obstacles for government actions begun before it took effect or within 15 years after, and it revives proceedings dismissed only because they were time‑barred. It also gives the statute the retroactive effect necessary to support actions arising from historical conduct. That creates both opportunity for recovery and legal risk — retroactivity will inform defences and jurisdictional litigation.
Apportionment when individual causation is unclear — statutory list of factors
When the government cannot identify which defendant caused a particular exposure, the court may apportion liability according to each defendant’s contribution to the risk of harm. The statute provides a non‑exhaustive list of factors (period on market, market share, potency, promotional spend, testing/warnings, leadership role, and continuation after knowledge of risk) that courts must consider when assigning percentages. That produces a structured but discretionary apportionment analysis.
Personal exposure for corporate leaders and contribution among defendants
Directors and officers who directed, authorized, assented to, acquiesced in or participated in corporate opioid‑related wrongs are jointly and severally liable with the corporation, subject to a due‑diligence defense. A defendant found liable can commence contribution proceedings against other liable defendants, and the court can apportion contribution under the same statutory factors used for risk‑based apportionment.
This bill is one of many.
Codify tracks hundreds of bills on this topic across all five countries.
Explore this topic in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Government of Yukon — gains a statutory tool to recover present value of past and projected health‑care spending tied to opioid harms and to participate or continue class proceedings where it is a class member, improving the territorial government’s fiscal recovery options.
- Government of Canada — obtains a parallel statutory remedy to seek federal program expenditures related to opioid harms and to use population‑level proof to quantify federal costs.
- Insured populations and health systems in Yukon — potential indirect benefit from recovered funds being redirected to public health programs, treatment and prevention, and from a legal framework that makes whole‑of‑government costs visible and litigable.
- Class‑action and public‑interest counsel — benefit from explicit admissibility of population‑based evidence and the ability to coordinate aggregate remedies and discovery orders that protect individual privacy while permitting testing of claims.
- Epidemiologists and forensic economists — see expanded demand for population‑level sampling, statistical causation studies and present‑value cost modelling under court supervision.
Who Bears the Cost
- Manufacturers, wholesalers and consultants (as broadly defined) — face direct exposure for past and future government health‑care costs, allocation of liability by market share or risk contribution, and expanded discovery and expert‑evidence battles.
- Directors and officers of corporations — face potential joint and several liability where they directed or participated in corporate misconduct, unless they successfully invoke the due‑diligence defence.
- Corporations’ litigation budgets and insurers — will bear increased defence and indemnity costs, and insurers may face coverage disputes given the retroactive application and potential for large aggregate awards.
- Courts and expert witnesses — will absorb new procedural complexity: determining what constitutes a statistically meaningful sample, adjudicating market‑share calculations over long historical windows, and supervising anonymized discovery.
- Settling parties and counterparties to prior agreements — will need to account for the Act’s limits on agreements that purported to bind Yukon and the rule that Yukon’s prior receipts are deducted from later recoveries, creating negotiation and accounting costs.
Key Issues
The Core Tension
The central dilemma is between efficiently restoring public health funds through aggregate, population‑level proof and protecting defendants’ rights to individualised causation and proportionate liability: the statute empowers governments to obtain large‑scale recoveries using presumptions and statistical evidence, but that efficiency risks imposing significant, potentially disproportionate liabilities on suppliers and corporate officers unless courts rigorously adjudicate sampling methods, market‑share calculations and apportionment factors.
The Act trades individualized proof for aggregate efficiency. By creating presumptions and admitting population‑level evidence it lowers plaintiffs’ proof burden for large‑scale recovery, but it also raises methodological disputes about appropriate sampling, baseline counterfactuals and the statistical linkage between promotion and usage.
Courts will have to police expert methodology without a clear statutory standard for what counts as a ‘statistically meaningful’ sample or for acceptable modelling assumptions.
The market‑share formulas and the statutory apportionment factors provide structure but are data‑intensive. Calculating quantities distributed, dispensed or purchased in Yukon over potentially long retroactive windows will require access to commercial records, importation/distribution data and historical prescribing or dispensing logs that may no longer exist or be fragmented across jurisdictions.
The Act’s retroactivity and revival of time‑barred suits amplify evidentiary and jurisdictional friction: defendants will challenge the availability, reliability and admissibility of old data while plaintiffs press courts for broader latitude to rely on extrapolation.
The Act also creates tension between remedial goals and fairness to defendants: statutory presumptions shift the evidentiary balance and may incentivize early settlements, but they also expose directors and corporations to joint and several liability that can yield disproportionate loss allocation unless courts carefully apply the rebuttal and apportionment mechanisms. Finally, the Act’s handling of prior agreements—nullifying their binding effect against Yukon while allowing deduction of earlier compensation—will generate transactional and litigation disputes about offsets, standing and the interaction with multijurisdictional class settlements.
There's more to this law than the bill.
Codify Laws traces every connection across the legislative lifecycle.